Pure Global

Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus - Trial NCT06152042

Access comprehensive clinical trial information for NCT06152042 through Pure Global AI's free database. This Phase 2 trial is sponsored by Biomea Fusion Inc. and is currently Not yet recruiting. The study focuses on Type 1 Diabetes Mellitus. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06152042
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06152042
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus
Phase 2 Randomized, Double-blind Trial of BMF-219 Compared to Placebo in Participants With Type 1 Diabetes Mellitus

Study Focus

Type 1 Diabetes Mellitus

BMF-219

Interventional

drug

Sponsor & Location

Biomea Fusion Inc.

Timeline & Enrollment

Phase 2

Nov 30, 2023

Aug 31, 2025

150 participants

Primary Outcome

To assess the effect on endogenous insulin secretion

Summary

Phase 2 Trial of BMF-219 in Participants with Type 1 Diabetes Mellitus.

ICD-10 Classifications

Type 1 diabetes mellitus
Type 1 diabetes mellitus with unspecified complications
Type 1 diabetes mellitus with other specified complications
Type 1 diabetes mellitus without complications
Type 1 diabetes mellitus with multiple complications

Data Source

ClinicalTrials.gov

NCT06152042

Non-Device Trial